JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $280
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $248 to $280.
August 26, 2024 | 2:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has maintained a Neutral rating on Alnylam Pharmaceuticals but increased the price target from $248 to $280, indicating a positive outlook.
The increase in price target from $248 to $280 by JP Morgan suggests a positive outlook for Alnylam Pharmaceuticals, which could lead to a short-term increase in stock price. However, the Neutral rating indicates that the analyst does not see a strong buy opportunity, balancing the impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100